Lisata Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview

Lisata Therapeutics

06/05/2025 23:37

Lisata Therapeutics Inc LSTA.OQ LSTA.O is expected to show no change in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

​LSEG's mean analyst estimate for Lisata Therapeutics Inc is for a loss of 53 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lisata Therapeutics Inc is $15.00​, above​ its last closing price of $2.30. ​​​

This summary was machine generated May 6 at 22:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)